Overview

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Status:
Recruiting
Trial end date:
2030-12-01
Target enrollment:
0
Participant gender:
All
Summary
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Navy General Hospital, Beijing
Criteria
Inclusion Criteria:

- Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

Exclusion Criteria:

- Involved sites other than the brain, meninges, CSF, or the eyes.

- Age less than 18 years or greater than 75 years.

- Inadequate bone marrow capacity (defined as neutrophils<1.5 ×10^9/L, platelets <100
×10^9/L, and hemoglobin level< 8 g/dL).

- Known cause of immunosuppression (ie, HIV type I infection).

- Any previous malignancy.

- Creatinine clearance below 60 mL/min.

- Heart insufficiency (NYHA IIIB or IV).

- Uncontrolled infection.

- Noncompensated active pulmonary or liver disease.

- Previously treated for PCNSL, except by corticosteroids.